Cardiovascular
-
Acoramidis Improves Cardiovascular Outcomes Rapidly in ATTR-CM Patients
BridgeBio Pharma’s acoramidis (Attruby®/BEYONTTRA®) shows rapid efficacy in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The ATTRibute-CM study revealed a 49% reduction in cardiovascular mortality or recurrent hospitalizations by Month 30. Extended follow-up showed a 45% reduction in cardiovascular mortality at Month 42 compared to placebo switch. Acoramidis, an oral TTR stabilizer, is approved in the US, Europe, Japan, and the UK, demonstrating near-complete TTR stabilization. It also mitigates rises in NT-proBNP levels.
